What are the Historical Developments and Current Growth Metrics of the Immunodiagnostics Market?
The immunodiagnostics market has seen considerable growth due to a variety of factors.
•The immunodiagnostics market has seen robust growth over recent past. Its size is set to increase from $22.88 billion in 2024 to $24.54 billion in 2025, marking a compound annual growth rate (CAGR) of 7.3%.
This growth during the historical period can be traced back to increasing occurrences of infectious diseases, a rise in autoimmune diseases, cancer detections and monitoring, global spread of infectious diseases, initiatives related to public health, and various screening programs.
What Does Future Hold for The Immunodiagnostics Market Size?
The immunodiagnostics market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the immunodiagnostics market is projected to experience robust growth. The expectation is that it will expand to reach "$33.14 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.8%.
The anticipated growth in this period can be credited to aspects such as pandemic readiness and response, the emergence of personalized medicine and biomarker discovery, expansion of healthcare infrastructure in developing markets, integration with laboratory information systems, and an increased prevalence of chronic diseases. The key trends to watch during the forecast period encompass technologies like multiplexing, point-of-care testing (POCT), continued exploration in biomarker discovery and personalized medicine, rising prominence of digital immunodiagnostics, and a trend towards liquid biopsy.
What Are The Primary Growth Drivers In The Immunodiagnostics Market?
The growth of the immunodiagnostics market is anticipated to be driven by the rising incidence of infectious diseases. These diseases are diseases that spread among individuals, caused by microbes such as bacteria, viruses, fungi, or parasites. Immunodiagnostic tests are used to detect a virus in a blood sample. For example, the Centers for Disease Control and Prevention, a US governmental body, reported in March 2024 that the number of tuberculosis cases had grown from 8,320 in 2022 to 9,615 in 2023, denoting an increase of 1,295 cases. Consequently, the escalating occurrence of infectious diseases is predicted to stimulate the immunodiagnostics market.
What Is The Segmentation Of The Global Immunodiagnostics Market?
The immunodiagnostics market covered in this report is segmented –
1) By Product: Reagents And Consumables, Instruments, Software And Services
2) By Technology: Enzyme-Linked Immunosorbent Assay, Chemiluminescence Immunoassay, Fluorescent Immunoassay, Radioimmunoassay, Rapid Test, Other Technologies
3) By Application: Infectious Diseases, Oncology And Endocrinology, Bone And Mineral Diseases, Autoimmunity Disorders, Cardiac Biomarkers, Drug Monitoring, Other Applications
4) By End User: Hospitals, Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users
Subsegments:
1) By Reagents And Consumables: Antibodies, Assay Kits, Buffers And Substrates
2) By Instruments: Immunoassay Analyzers, Flow Cytometers, ELISA Readers
3) By Software And Services: Laboratory Information Management Systems (LIMS), Data Analysis Software, Maintenance And Support Services
Pre-Book The Immunodiagnostics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Immunodiagnostics Market Landscape?
Key players in the immunodiagnostics market are concentrating their efforts on creating novel solutions like the S. pneumoniae antigen immunodiagnostic assay, which is instrumental in identifying pneumococcal pneumonia infection. This assay is designed to spot the presence of Streptococcus pneumoniae antigens in the human body's fluids, thereby helping to confirm pneumococcal infections. As an example, DiaSorin S.p.A., a biotechnology firm based in Italy, introduced the LIAISON S. pneumoniae antigen immunodiagnostic assay in September 2024. This diagnostic test is specifically intended to qualitatively detect Streptococcus pneumoniae antigens in adult urine samples suspected of carrying pneumococcal pneumonia. Notably, this assay provides a speedy solution enabling healthcare providers to promptly diagnose pneumococcal pneumonia and differentiate it from other respiratory infections. Utilizing the LIAISON CLIA analyzers, the test delivers results in merely 35 minutes, expediting immediate and precise antimicrobial treatment. Moreover, its capacity to identify up to 91 serotypes boosts clinical decision-making and promotes effective antibiotic use. This significant breakthrough in the immunodiagnostics sector is particularly relevant for fighting community-acquired pneumonia.
Who Are the Key Players in the Immunodiagnostics Market?
Major companies operating in the immunodiagnostics market include:
• Abbott Laboratories
• Arkray Inc.
• bioMérieux Inc.
• Immunodiagnostic Systems Holdings Plc (IDS)
• Bio-Rad Laboratories Inc.
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services Inc.
• Siemens AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Qiagen N.V.
• Tecan Trading AG
• PerkinElmer Inc.
• Merck KGaA
• Becton Dickinson and Company
• Grifols S.A.
• Ortho Clinical Diagnostics
• Beckman Coulter Inc.
• Bio-Techne Corporation
• Creative Diagnostics
• Fujirebio Holdings Inc.
• Gold Standard Diagnostics Corp.
• Hologic Inc.
• Luminex Corporation
• Myriad Genetics Inc.
• Natera Inc.
• OraSure Technologies Inc.
• Quidel Corporation
What are the Regional Insights into the Immunodiagnostics Market?
North America was the largest region in the immunodiagnostics market in 2024. The regions covered in the immunodiagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
